Notable Labs Corp (NTBL): Rega marang dodolan
Notable Labs, Ltd. (NTBL) is developing the advanced PPMP IT system to analyze therapy efficacy on live cells. The method is based on the functional diagnostics of thousands of drugs to determine the ideal treatment. The median P/S helps assess the business value relative to revenue, where 7.70 captures the magnitude of this parameter. The process is completed by a streamlined express bio-sample transport network, ensuring the accuracy of laboratory research.
Rincian metrik lan analitis perusahaan Notable Labs Inc. (NTBL)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- data nilai buku modal saham:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Notable Labs, Ltd.|NTBL - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Notable Labs Corp|NTBL - Gunggung utang perusahaan|Utang-utang marang nilai buku Notable Labs Inc.|NTBL - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Notable Labs|Likuiditas cepet notablelabs.com
- statistik bathi lan rasio pasar:
NTBL - Bathi resik|Proyeksi bathi mangsa ngarep Notable Labs, Ltd.|NTBL - Pangali P/E|Rega marang bathi mangsa ngarep Notable Labs Ltd|NTBL - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Notable Labs Inc.|NTBL - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Notable Labs|NTBL - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan notablelabs.com|NTBL - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Notable Labs, Ltd.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:NTBL - notablelabs.com
Notable Labs, Ltd. (NTBL) independence from macroeconomic cycles and the steady demand for medtech innovations make the current P/S ratio a key indicator of market confidence in the company's capital-intensive business development. This metric reflects the company's valuation relative to its revenue, allowing investors to assess the premium paid for every dollar of sales and determine the extent to which quotes are overvalued relative to actual operating income.
Karo sapa Notable Labs, Ltd. saingan
beigene.com - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Halozyme HALO|Revolution Medicines Inc (RVMD) - Rega marang dodolan|AAPG: Kapitalisasi marang pendapatan|CG Oncology Therapeutics - Kapitalisasi marang volume dodolan|URGN: Multiplikator P/S|bicara.com (BCAX) - Multiplikator P/S|PSNL (Personalis) - Multiplikator P/S|Rasio rega marang pendapatan ERAS|Rasio rega marang pendapatan Delcath (DCTH)|Rasio rega marang pendapatan YMAB (Y-mAbs Corp)|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Candel Therapeutics Inc. (CADL) - Rega marang dodolan|ARAY: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SLS (SELLAS Life Sciences)|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|CTOR (Citius Oncology Inc) - Rasio rega marang pendapatan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|Multiplikator P/S protaratx.com|Multiplikator P/S FATE|Rasio rega marang pendapatan WHWK (aadibio.com)|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|Koefisien rega marang pendapatan Champions Oncology Inc (CSBR)|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (CEL-SCI Corporation)|OS Therapies (OSTX) - Rasio rega marang pendapatan|RADX (radiopharmtheranostics.com) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan ARTV|ANL (Adlai Nortye Limited) - Kapitalisasi marang volume dodolan|Multiplikator P/S VERU|tempesttx.com - Rasio kapitalisasi marang pendapatan|Xilio Therapeutics - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Renovaro Biosciences (RENB)|MURA - Rasio rega marang pendapatan|KAPA (Kairos Pharma Ltd) - Rasio kapitalisasi marang pendapatan|OKUR (onkuretherapeutics.com) - Kapitalisasi marang pendapatan|GDTC: Kapitalisasi marang volume dodolan|CRIS (Curis Inc.) - Multiplikator P/S|Rasio rega marang pendapatan APLM|Rasio rega marang pendapatan Tharimmune Corp (THAR)|Rasio rega marang pendapatan ADVB (advanbiomed.com)|Multiplikator P/S GNPX (Genprex, Inc.)|CLDI - Kapitalisasi marang pendapatan|Sunshine Biopharma, Inc. - Multiplikator P/S|XBIO - Multiplikator P/S|Salarius (SLRX) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan PPBT|AONC (American Oncology Network Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan beigene.com (BGNE)|Multiplikator P/S CKPT|ELEV - Rega marang dodolan|Rasio rega marang pendapatan iCAD ICAD|Rasio kapitalisasi pasar marang pendapatan IKNA|VIRX: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA: Multiplikator P/S|Kapitalisasi marang pendapatan Ascentage Pharma Group International
